Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers

Biochemical and Biophysical Research Communications

Volumn 424, Issue 1, 2012, Pages 34-39

  Poletto, Mattia ^a   Loreto, Carla Di ^a   Marasco, Daniela ^b,c   Poletto, Elena ^a   Puglisi, Fabio ^a   Damante, Giuseppe ^a   Tell, Gianluca ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CNR   (Italy)

Author keywords

Acetylation; Apurinic apyrimidinic endonuclease redox effector factor 1 (APE1 Ref 1); Base excision repair (BER); Triple negative breast cancer (TNBC)

Indexed keywords

LYSINE DERIVATIVE; POLYCLONAL ANTIBODY; REDOX EFFECTOR FACTOR 1;

ACETYLATION; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TRIPLE NEGATIVE BREAST CANCER;

ACETYLATION; AMINO ACID SEQUENCE; BREAST NEOPLASMS; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FEMALE; HUMANS; LYSINE; MOLECULAR SEQUENCE DATA; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 84864083812     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.039     Document Type: Article

References (34)

1. Walsh C.T., Garneau-Tsodikova S., Gatto G.J. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew. Chem. Int. Ed. Engl. 2005, 44:7342-7372.
2. Yang X.J., Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 2008, 31:449-461.
3. Close P., Creppe C., Gillard M., et al. The emerging role of lysine acetylation of non-nuclear proteins. Cell. Mol. Life Sci. 2010, 67:1255-1264.
4. Tell G., Damante G., Caldwell D., et al. The intracellular localization of APE1/Ref-1: more than a passive phenomenon?. Antioxid. Redox Signal. 2005, 7:367-384.
5. Vascotto C., Cesaratto L., Zeef L.A., et al. Genome-wide analysis and proteomic studies reveal APE1/Ref-1 multifunctional role in mammalian cells. Proteomics 2009, 9:1058-1074.
6. Tell G., Fantini D., Quadrifoglio F. Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment. Cell. Mol. Life Sci. 2010, 67:3589-3608.
7. Tell G., Wilson D.M., Lee C.H. Intrusion of a DNA repair protein in the RNome world: is this the beginning of a new era?. Mol. Cell. Biol. 2010, 30:366-371.
8. Busso C.S., Lake M.W., Izumi T. Posttranslational modification of mammalian AP endonuclease (APE1). Cell. Mol. Life Sci. 2010, 67:3609-3620.
9. Bhakat K.K., Izumi T., Yang S.H., et al. Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene. EMBO J. 2003, 22:6299-6309.
10. Yamamori T., DeRicco J., Naqvi A., et al. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res. 2010, 38:832-845.
11. Sengupta S., Mantha A.K., Mitra S., et al. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene 2011, 30:482-493.
12. Fantini D., Vascotto C., Marasco D., et al. Critical lysine residues within the overlooked N-terminal domain of human APE1 regulate its biological functions. Nucleic Acids Res. 2010, 38:8239-8256.
13. Kakolyris S., Kaklamanis L., Engels K., et al. Human AP endonuclease I (HAPI) protein expression inbreast cancer correlates with lymph node status and angiogenesis. Br. J. Cancer 1998, 77:1169-1173.
14. Robertson K.A., Bullock H.A., Xu Y., et al. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 2001, 61:2220-2225.
15. Di Maso V., Avellini C., Crocè L.S. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol. Med. 2007, 13:89-96.
16. Sheng Q., Zhang Y., Wang R., et al. Prognostic significance of APE1 cytoplasmic localization in human epithelial ovarian cancer. Med. Oncol. 2012, 29:1265-1271.
17. Fields G.B., Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990, 35:161-214.
18. Garbutt G.J., Abraham E.C. Non-enzymatic acetylation of human hemoglobins. Biochim. Biophys. Acta 1981, 670:190-194.
19. Schägger H. Tricine-SDS-PAGE. Nat. Protoc. 2006, 1:16-22.
20. Vascotto C., Fantini D., Romanello M., et al. APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process. Mol. Cell. Biol. 2009, 29:1834-1854.
21. Johnsson B., Lofas S., Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 1991, 198:268-277.
22. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363:1938-1948.
23. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008, 26:2568-2581.
24. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
25. Andreetta C., Minisini A.M., Miscoria M., et al. First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit. Rev. Oncol. Hematol. 2010, 76:99-111.
26. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26:1275-1281.
27. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
28. Oakman C., Moretti E., Pacini G., et al. Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. Eur. J. Cancer 2011, 47(Suppl 3):S370-S372.
29. Ma C.X., Luo J., Ellis M.J. Molecular profiling of triple negative breast cancer. Breast Dis. 2010, 32:73-84.
30. Puglisi F., Barbone F., Tell G., et al. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncol. Rep. 2002, 9:11-17.
31. Curtis C.D., Thorngren D.L., Ziegler Y.S., et al. Apurinic/apyrimidinic endonuclease 1 alters estrogen receptor activity and estrogen-responsive gene expression. Mol. Endocrinol. 2009, 23:1346-1359.
32. Kelley M.R. DNA Repair In Cancer Therapy. Molecular Targets and Clinical Applications 2012, Academic Press. first ed.
33. Sultana R., McNeill D.R., Abbotts R., et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int. J. Cancer 2012, 10.1002/ijc.27512.
34. Saha T., Smulson M., Rosen E.M. BRCA1 regulation of base excision repair pathway. Cell Cycle 2010, 9:2471-2472.